Author:
Contag Caitlin A.,Mische Leah,Fong Isabel,Karan Abraar,Vaidya Akanksha,McCormick David W.,Bower William,Hacker Jill K.,Johnson Kelly,SanJuan Perla,Crebbin Linda,Temmins Caroline,Sahni Harleen,Bogler Yael,Cooper Joseph D.,Narasimhan Supriya
Publisher
Centers for Disease Control and Prevention (CDC)
Subject
Infectious Diseases,Microbiology (medical),Epidemiology
Reference15 articles.
1. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.;Duraffour;Antivir Ther,2007
2. Tecovirimat: first global approval.;Hoy;Drugs,2018
3. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.;Duraffour;J Antimicrob Chemother,2015
4. Centers for Disease Control and Prevention. Guidance for tecovirimat use. Updated 2023 Feb 23 [cited 2023 Jun 6]. https://www.cdc.gov/poxvirus/mpox/clinicians/Tecovirimat.html
5. US National Library of Medicine. Study of tecovirimat for human monkeypox virus. STOMP Trial. Updated 2023 Aug [cited 2023 Oct 11]. https://clinicaltrials.gov/ct2/show/NCT05534984
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献